Perrigo (PRGO) to Settle Hatch-Waxman Litigation Over Generic Ofirmev
Tweet
Share
E-mailGet Alerts PRGO Hot Sheet
Price: $14.66 +0.14%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 8.1%
Revenue Growth %: -3.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 8.1%
Revenue Growth %: -3.8%
Join SI Premium – FREE
Perrigo Co (Nasdaq: PRGO) has agreed to settle its Hatch-Waxman litigation relating to Ofirmev (acetaminophen) injection brought by Cadence Pharmaceuticals, Inc. (Nasdaq: CADX).
Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev (acetaminophen) injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.
Ofirmev (acetaminophen) injection is administered intravenously as a single or repeated dose therapy for the reduction of fever and the treatment of mild to severe pain with or without adjunctive opioid analgesics. Ofirmev has annual sales of approximately $42 million, as measured by Wolters Kluwer.
Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev (acetaminophen) injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.
Ofirmev (acetaminophen) injection is administered intravenously as a single or repeated dose therapy for the reduction of fever and the treatment of mild to severe pain with or without adjunctive opioid analgesics. Ofirmev has annual sales of approximately $42 million, as measured by Wolters Kluwer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sparton, Glen Eagle ink joint venture deal for Ontario silver mine
- Sonos launches OS 27 with AI control and two new products
- Can-Am to provide $150,000 and vehicles to Farm Rescue over three years
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
